Smiths Medical (London) in January reported plans to establish a subsidiary in Mumbai, India.

“India is one of the most dynamic health care markets in the world,“ said Srini Seshadri, president of Smiths Medical. “By creating an Indian subsidiary, we are demonstrating our commitment to investing in this market, growing our business and becoming part of the fabric of the regional health care community.“

Ashwin Benegal is the general manager of Smiths Medical's Indian Operations. He joined the company in 2008 and brings with him more than 15 years of medical device experience, having worked in several large multi-national corporations.

Rochester agrees to buy Laprolan

Rochester Medical (Stewartville, Minnesota) said it has agreed to buy Laprolan (Beuningen, the Netherlands), a medical supplies distribution company, from Fornix (Lelysted, the Netherlands). Rochester Medical will pay nearly €10.35 million ($13.73 million) in cash for the shares of Laprolan. The transaction is subject to approval by the shareowners of Fornix and is expected to close by the end of May but will have a retroactive effective date of Jan. 1.

PerkinElmer collaborates with Italian hospital

PerkinElmer (Waltham, Massachusetts) and the Meyer Children's Hospital of Florence (Italy), a leading Italian research center, are working together to develop an early stage neonatal diagnostic test for Tyrosinemia Type I, a rare metabolic genetic disease that is lethal if untreated, but curable if detected early.

Tyrosinemia Type I is an enzymatic deficiency that causes an inability to break down the amino acid tyrosine, which synthesizes proteins. Symptoms of Tyrosinemia Type I appear in the first few months of life, and if untreated, tyrosine accumulation can lead to kidney and liver failure, severe nervous system disorders, and possibly liver tumors.

The NeoBase test developed by PerkinElmer and Meyer is capable of screening newborns for the disease within the first 48 hours of life, enabling rapid diagnosis and immediate intervention by clinicians, through diet modification, medication or surgery. The screening test, which identifies the disease via the Succinylacetone marker in a single drop of blood, is 100% specific for detecting Tyrosinemia Type I.